Vision related quality of life and topical glaucoma treatment side effects

Health and Quality of Life Outcomes

Volumn 1, Issue , 2003, Pages

  Nordmann, Jean Philippe ^a   Auzanneau, Nadia ^b   Ricard, Séverine ^b   Berdeaux, Gilles ^b  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b Taylor Nelson Sofres Santé ^*  (France)

Author keywords

Glaucoma; Quality of life; Side effects; Topical treatment

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; MIOTIC AGENT; PROSTAGLANDIN; ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; AUTOMATION; BURNING SENSATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRIVING ABILITY; DRUG TOLERABILITY; DRY EYE; FEMALE; FRANCE; GLAUCOMA; HEALTH STATUS; HEALTH SURVEY; HUMAN; INTRAOCULAR HYPERTENSION; LACRIMAL GLAND DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NIGHT VISION; PATIENT SATISFACTION; POSTAL MAIL; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT; VISUAL DISORDER; VISUAL IMPAIRMENT; VISUAL SYSTEM FUNCTION; AGED; ANALYSIS OF VARIANCE; CROSS-SECTIONAL STUDY; DRUG EFFECT; EVALUATION; MIDDLE AGED; SOCIOECONOMICS; TOPICAL DRUG ADMINISTRATION; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; GLAUCOMA; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRES; SOCIOECONOMIC FACTORS; VISUAL ACUITY;

EID: 4243185852     PISSN: 14777525     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-7525-1-75     Document Type: Article

References (56)

1. Goldstein H: Magnitude and causes of blindness : Sources and limitations of data. In clinical ophthalmology Volume 5. Issue 52 Edited by: Freemann JS. Lippincott Company, Philadelphia, The USA; 1990:1-10.
2. Mitchell P, Smith W, Attebo K, Healey PR: Prevalence of open-angle glaucoma in Australia. The Blue Mountains eye study. Ophthalmology 1996, 103:1661-9.
3. Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, Menage MJ: Prevalence of glaucoma. The Beaver Dam Eye study,. Ophthalmology 1992, 99:1499-1504.
4. Ekstrom C: Prevalence of open-angle glaucoma in central Sweden. The Tierp glaucoma survey. Acta Ophthalmologica Scandinavica 1996, 74:107-12.
5. Bengtsonn B: The prevalence of glaucoma. British Journal ofOphthalmology 1981, 65:46-9.
6. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS, Dawber TR: The Framingham eye study. I. Outline and major prevalence findings. II. Associations of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. American Journal of Epidemiology 1977, 106:33-41.
7. Kahn HA, Milton RC: Alternative definitions of open angle glaucoma. Effects on prevalence and associations in the Framingham Eye Study. Archives of Ophthalmology 1980, 98:2172-7.
8. Kahn HA, Milton RC: Revised Framingham eye study prevalence of glaucoma and diabetic retinopathy. American Journal of Epidemiology 1980, 111:769-76.
9. Martinez GS, Campbell AJ, Reinken J, Allan BC: Prevalence of ocular disease in population 65 years old and older. American Journal of Ophthalmology 1982, 94:181-189.
10. Podgor MJ, Leske MC, Ederer F: Incidence estimates for lens changes, macular changes, open-angle glaucoma and diabetic retinopathy. American Journal of Epidemiology 1983, 118:206-212.
11. Tuck MW, Crick RP: The age distribution of primary open angle glaucoma. Ophthalmic Epidemiology 1998, 5:173-183.
12. Quigley HA, Vitale S: Models of open-angle glaucoma prevalence and incidence in the United States. Investigative Ophthalmology and Visual Science 1997, 38:83-91.
13. Armaly MF: Ocular pressure and visual fields : A ten-year follow-up study. Arch Ophthalmol 1969, 81:25-44.
14. Rota-Bartelink AM, Pitt A, Story I: Influence of diurnal variation on the intraocular pressure measurement of treated primary open-angle glaucoma during office hours. J Glaucoma 1996, 5(6):410-5.
15. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K: Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000, 9(2):134-42.
16. Gonzalez I, Pablo LE, Pueyo M, Ferrer E, Melcon B, Abecia E, Honrubia FM: Assessment of diurnal tensional curve in early glaucoma damage. Int Ophthalmol 1997, 20(1-3):113-5.
17. Zeimer RC, Wilensky JT, Gieser DK, Viana MAG: Association between intra-ocular pressure peaks and progression of visual field loss. Ophthalmology 1991, 98(1):64-69.
18. The AGIS investigators: The advanced glaucoma intervention study (AGIS) : 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology 2000, 130(4):429-440.
19. Kitazawa Y, Horie T, Aoki S: Untreated ocular hypertension. A long-term prospective study. Arch Ophthalmol 1977, 95:1180-1189.
20. Anderson DR: The management of elevated intraocular pressure with normal optic discs and visual fields. Surv Ophthalmol 1977, 21:479-89.
21. Fingeret M: Glaucoma medications, glaucoma therapy, and the evolving paradigm. J Am Optom Assoc 1998, 69(2):115-21.
22. Reyes E, Izquierdo NJ, Blasini M: Adverse drugs reactions associated with glaucoma medications. Bol Asoc Med P R 1997, 89(4-6):51-5.
23. Odberg T, Jakobsen JE, Hultgren SJ, Halseide R: The impact of glaucoma on the quality of life of patients in Norway. II. Patient response correlated to objective data. Acta Ophthalmologica Scandinavica 2001, 79:121-4.
24. Odberg T, Jakobsen JE, Hultgren SJ, Halseide R: The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire. Acta Ophthalmologica Scandinavica 2001, 79:116-20.
25. Mills RP, Janz NK, Wren PA, Guire KE: Correlation of visual field with quality-of-life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS). Journal of Glaucoma 2001, 10:192-198.
26. Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE: Quality of life in newly diagnosed glaucoma patients : The collaborative Initial Glaucoma Treatment Study. Ophthalmology 2001, 108:887-97.
27. Sherwood MB, Garcia-Siekavizza A, Meltzer MI, Hebert A, Burns AF, McGorray S: Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study. Ophthalmology 1998, 105:561-6.
28. Mills RP: Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis. Transactions of the American Ophthalmological Society 1998, 96:753-812.
29. Parrish RK, Gedde SJ, Scott IU, Feuer WJ, Schiffman JC, Mangione CM, Montenegro-Piniella A: Visual function and quality of life among patients with glaucoma. Archives of Ophthalmology 1997, 115:1447-55.
30. Parrish RK: Visual impairment, visual functioning, and quality of life assessments in patients with glaucoma. Transactions of the American Ophthalmological Society 1996, 94:919-1028.
31. Wilson MR, Coleman AL, Yu F, Bing EG, Sasaki IF, Berlin K, Win J, Lai A: Functional status and well being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Ophthalmology 1998, 105:2112-6.
32. Marchetti A, Magar R, An P, Nichol M: Clinical and economic impact of new trends in glaucoma treatment. MedGenMed [serial online] 2001, 3:6.
33. Cantor LB, Hoop J, Katz LJ, Flartey K, Alphagan/Betaxol Clinical Study Group: Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure. Clin Ther 2001, 23:1032-9.
34. Javitt JC, Schiffman RM: Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. Journal of Glaucoma 2000, 9:224-34.
35. Javitt J, Goldberg I: Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. Journal of Glaucoma 2000, 9:398-408.
36. Lee DA, Gornbein JA: Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. Journal of Glaucoma 2001, 10:220-6.
37. Strohmaier K, Snyder E, Adamsons I: A multicenter study comparing dorzolamide and pilocarpine as adjunctive therapy to timolol: patient preference and impact on daily life. Journal of the American Optometric Association 1998, 69:441-51.
38. Gutierrez P, Wilson MR, Johnson C, Gordon M, Cioffi GA, Ritch R, Sherwood M, Meng K, Mangione CM: Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol 1997, 115:777-84.
39. Wandell PE, Lundstrom M, Brorsson B, Aberg H: Quality of life among patients with glaucoma in Sweden. Acta Ophthalmol Scand 1997, 75:584-8.
40. Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA: Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology 1997, 104:334-42.
41. Barber BL, Santanello NC: Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics 1995, 33:598-604.
42. INSEE 2000 [http://www.insee.fr/].
43. Rouillon F, Blachier C, Dreyfus JP, Bouhassira M, Allicar MP: Etude pharmaco-épidémiologique de la consommation des antidépresseurs en population génŗale. L'Encé phale 1996, Sp I.:39-48.
44. Frexinos J, Denis P, Allemand H, Allouche S, Los F, Bonnelye G: Etude descriptive des symptômes fonctionnels digestifs dans la population générale française. Gastroenterol Clin Biol 1998, 22:785-91.
45. Antona D, Guérin N: Couverture vaccinale rougeole - rubéole - oreillons en France en 1998 : première et deuxième doses. BEH 1999, 19:74-5.
46. Le Pen C, Levy E: Socio-économie de la maladie veineuse : les enseignements d'une enquête sur les consommateurs de médicaments phlébotoniques en France. Phlébologie 1993, 46(no 1):47-63.
47. Mangione CM: The National Eye Institute 25-item Visual Function, Questionnaire (VFQ-25) - Scoring algorithm. 2000:1-15.
48. Mangione CM, Berry S, Spritzer K, Kanz NK, Klein R, Owsley C, LPP: Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Archives of Ophthalmology 1998, 116:227-33
49. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD: Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Archives of Ophthalmology 1998, 116:1496-504.
50. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RI, National Eye Institute Visual Function Questionnaire Field Test Investigators: Development of the 25-item National Eye Institute Visual Function Questionnaire. Archives of Ophthalmology 2001, 119(7):1050-1058
51. Nordmann JP, Sullivan K, Viala M, Arnoult B, Berdeaux G: Psychometric validation of the NEI-VFQ 25 French version in a population of patients treated for ocular hypertension and glaucoma. PharmacoEconomics in press.
52. Vidal. Ed du Vidal, Paris 2001.
53. International Medical Statistics, Paris 2001.
54. Guttman L: The qualification of a class of attributes: a theory and method of a scale construction. In: The Prediction of Personal Adjustment Edited by: Horst P. New York: SSCR; 1941:251-264.
55. Burt C: The factorial analysis of qualitative data. British Journal of Statistical Psychology 1950, 3:166-185.
56. Hayashi C: Theory and examples of quantification (II). Proceedings of the Institute of Statistics and Mathematics 1956, 4:19-30.